Physician profile
Phi V Tran
NPI 1124092929
$2,952.83
in general payments reported to CMS, 2019-2025
12 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2023: $403 · 2024: $1,054 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,795.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,706.99 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $346.23 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $201.65 | 2023-2024 | Ozempic, Rybelsus |
| Amgen INC. | $161.46 | 2023-2025 | Prolia, Repatha, Otezla |
| Amarin Pharma, INC. | $157.59 | 2019 | |
| Gilead Sciences, INC. | $141.98 | 2025 | |
| Corcept Therapeutics | $75.26 | 2024 | Korlym |
| Lilly USA, LLC | $53.06 | 2023-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.09 | 2025 | Jardiance |
| Ferring Pharmaceuticals INC. | $20.87 | 2023 | Rebyota |
| Exact Sciences Corporation | $20.17 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $17.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phi Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.